Autoimmune Association and 50+ Patient Groups Send Letter to Key Members of Congress on Drug Pricing Priorities for Autoimmune Patients
Washington, DC, July 30, 2021 – Autoimmune Association sent a letter to key members of Congress with the undersigned 50+ patient groups on the importance of drug pricing policy concerns, priorities, and solutions for individuals living with autoimmune disease.
At a high-level, the letter focuses on the following concerns;
- Concerns With Foreign-Reference Pricing
- QALY as Discriminatory
- Access Restrictions to Medicines Now, Lack of Future Cures
We also suggest patient-focused policy solutions;
- Counting Copay Assistance Toward Deductible, Out-of-Pocket Caps
- Ensuring Discounts Go Directly to Patient
- Addressing Rebates in the System, Highlighting PBM Practices
Specifically, the letter went to House and Senate leadership, House E&C, Senate HELP, and Senate Finance, and the group of 10 democrats who wrote a letter to Speaker Pelosi regarding concerns for certain drug pricing policies under HR3.
Autoimmune Association is the nation’s only nonprofit organization dedicated to bringing a national focus to autoimmunity as a category of disease and a major women’s health issue and promoting a collaborative research effort in order to find better treatments and a cure for all autoimmune diseases.
For upcoming Autoimmune Association events visit Events Calendar at www.aarda.org. For more information, visit www.aarda.org. Follow us on social media: Facebook, Twitter, LinkedIn, Instagram, and YouTube.
Join our email list
Receive the latest blog articles, news, and more right to your inbox!
Related articles you might be interested in
Find more resources on autoimmunity
Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.